相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。TIMP-1 Induces an EMT-Like Phenotypic Conversion in MDCK Cells Independent of Its MMP-Inhibitory Domain
Young Suk Jung et al.
PLOS ONE (2012)
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration
Douglas G. Altman et al.
PLOS MEDICINE (2012)
Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2011)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Role of serum matrix metalloproteinase-2 and-9 to predict breast cancer progression
Suprava Patel et al.
CLINICAL BIOCHEMISTRY (2011)
Multiplexed Homogeneous Proximity Ligation Assays for High-throughput Protein Biomarker Research in Serological Material
Martin Lundberg et al.
MOLECULAR & CELLULAR PROTEOMICS (2011)
The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise
Susanne Moller et al.
ACTA ONCOLOGICA (2008)
Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer
Zheng-Sheng Wu et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
A comparative study of tissue inhibitor of metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer
Anne-Sofie Schrohl et al.
TUMOR BIOLOGY (2008)
Plasma and serum levels of tissue inhibitor of metalloproteinases-1 are associated with prognosis in node-negative breast cancer
Sidse Ornbjerg Wurtz et al.
MOLECULAR & CELLULAR PROTEOMICS (2008)
A biochemical model of matrix metalloproteinase 9 activation and inhibition
Prakash Vempati et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Latent MMP-9 is bound to TIMP-1 before secretion
Martin Roderfeld et al.
BIOLOGICAL CHEMISTRY (2007)
Rapid and individual-specific glycoprofiling of the low abundance N-glycosylated protein tissue inhibitor of metalloproteinases
Morten Thaysen-Andersen et al.
MOLECULAR & CELLULAR PROTEOMICS (2007)
TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis
M. L. Davidsen et al.
BRITISH JOURNAL OF CANCER (2006)
Circulating MMP2 and MMP9 in breast cancer - Potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories
Stella B. Somiari et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein
Ki-Kyung Jung et al.
EMBO JOURNAL (2006)
The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients
CA Fernández et al.
CLINICAL CANCER RESEARCH (2005)
Measurement of the uncomplexed fraction of tissue inhibitor of metalloproteinases-1 in the prognostic evaluation of primary breast cancer patients
SO Würtz et al.
MOLECULAR & CELLULAR PROTEOMICS (2005)
Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer
AS Schrohl et al.
CLINICAL CANCER RESEARCH (2004)
Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with special reference to activator protein-2, HER2, and prognosis
JM Pellikainen et al.
CLINICAL CANCER RESEARCH (2004)
TIMP-1 inhibits apoptosis in breast carcinoma cells via a pathway involving pertussis toxin-sensitive G protein and c-Src
SJ Lee et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway
XW Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients
SM Ranuncolo et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Tissue inhibitor of metalloproteinases-1 signalling pathway leading to erythroid cell survival
E Lambert et al.
BIOCHEMICAL JOURNAL (2003)
Matrix metalloproteinases and tissue inhibitors of metalloproteinases - Structure, function, and biochemistry
R Visse et al.
CIRCULATION RESEARCH (2003)
Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer
AS Schrohl et al.
MOLECULAR & CELLULAR PROTEOMICS (2003)
Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis
L Nakopoulou et al.
JOURNAL OF PATHOLOGY (2002)
Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition - Implications for reversibility of liver fibrosis
FR Murphy et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
New functions for the matrix metalloproteinases in cancer progression
M Egeblad et al.
NATURE REVIEWS CANCER (2002)
分享论文
